284493-72-7

Basic information

• Product Name: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(4-FLUOROPHENYL)PROPANOIC ACID
• Synonyms: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(4-FLUOROPHENYL)PROPANOIC ACID;3-TERT-BUTOXYCARBONYLAMINO-3-(4-FLUORO-PHENYL)-PROPIONIC ACID;3-N-(TERT-BUTOXYCARBONYL)-AMINO-3-(4-FLUOROPHENYL)PROPIONIC ACID;3-N-BOC-AMINO-3-(4-FLUOROPHENYL)PROPIONIC ACID;3-(BOC-AMINO)-3-(4-FLUOROPHENYL)PROPIONIC ACID;RARECHEM AK HT T330;3-(BOC-AMINO)-3-(4-FLUOROPHENYL)PROPIONIC ACID, 98+%;3-N-BOC-Amino-3-(4-fluorophenyl)propionic acid,95%
• CAS NO: 284493-72-7
• Molecular Formula: C14H18FNO4
• Molecular Weight: 283.3
• EINECS: 604-604-1
• Mol File: 284493-72-7.mol

Chemical Properties

• Melting Point: 152-154°C (dec.)
• Boiling Point: 424.5 °C at 760 mmHg
• Flash Point: 210.5 °C
• Appearance: /
• Density: 1.1918 (estimate)
• Vapor Pressure: 5.8E-08mmHg at 25°C
• Storage Temp.: Freezer (-20°C)
• CAS DataBase Reference: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(4-FLUOROPHENYL)PROPANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(4-FLUOROPHENYL)PROPANOIC ACID(284493-72-7)
• EPA Substance Registry System: 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(4-FLUOROPHENYL)PROPANOIC ACID(284493-72-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• HazardClass: IRRITANT
• Hazardous Substances Data: 284493-72-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(4-FLUOROPHENYL)PROPANOIC ACID is used as a reagent for the study of potent, selective, and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors. 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(4-FLUOROPHENYL)PROPANOIC ACID plays a vital role in the development of new treatments for neurodegenerative diseases, particularly Parkinson's, by targeting the LRRK2 enzyme and modulating its activity.
Used in Research and Development:
In the field of research and development, 3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(4-FLUOROPHENYL)PROPANOIC ACID is utilized as a key component in the synthesis and evaluation of novel LRRK2 inhibitors. This helps scientists and researchers to better understand the underlying mechanisms of neurodegenerative diseases and develop more effective therapeutic strategies.
Used in Drug Design and Synthesis:
3-[(TERT-BUTOXYCARBONYL)AMINO]-3-(4-FLUOROPHENYL)PROPANOIC ACID is employed as a building block in the design and synthesis of new LRRK2 inhibitors. Its unique chemical properties allow for the creation of various derivative compounds with potential applications in the treatment of neurodegenerative diseases, enhancing the drug discovery process and offering new avenues for therapeutic intervention.

InChI:InChI=1/C14H18FNO4/c1-14(2,3)20-13(19)16-11(8-12(17)18)9-4-6-10(15)7-5-9/h4-7,11H,8H2,1-3H3,(H,16,19)(H,17,18)/p-1/t11-/m1/s1

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 
• 325-89-3 3-amino-3-(4-fluorophenyl)propanoic acid 

Relevant articles and documents

1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases/injuries associated with activated unfolded protein response pathways, such as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt- Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.